Earnings summaries and quarterly performance for Ardent Health.
Executive leadership at Ardent Health.
Board of directors at Ardent Health.
ER
Edmondo Robinson
Detailed
Director
EH
Ellen Havdala
Detailed
Director
MS
Mark Sotir
Detailed
Chairman of the Board
PB
Peter Bulgarelli
Detailed
Director
PB
Peter Bynoe
Detailed
Director
RS
Rahul Sen
Detailed
Director
RW
Rob Webb
Detailed
Director
RA
Robert A. DeMichiei
Detailed
Director
SC
Suzanne Campion
Detailed
Director
WG
William Goodyear
Detailed
Director
Research analysts who have asked questions during Ardent Health earnings calls.
BR
Benjamin Rossi
JPMorgan Chase & Co.
6 questions for ARDT
Also covers: AMED, AVAH, CON +7 more
CH
Craig Hettenbach
Morgan Stanley
6 questions for ARDT
Also covers: ACCD, AMWL, DH +10 more
AH
Ann Hynes
Mizuho Financial Group
4 questions for ARDT
Also covers: ACHC, BTSG, CI +21 more
Benjamin Hendrix
RBC Capital Markets
4 questions for ARDT
Also covers: ACHC, ADUS, AHCO +25 more
JG
Joanna Gajuk
Bank of America
4 questions for ARDT
Also covers: ACHC, ADC, ADUS +22 more
MG
Matthew Gillmor
KeyCorp
4 questions for ARDT
Also covers: ACHC, ADUS, ALHC +12 more
TG
Timothy Greaves
Loop Capital Markets LLC
4 questions for ARDT
Also covers: PRCH, WEAV
Raj Kumar
Stephens
3 questions for ARDT
Also covers: ACHC, ADUS, ALHC +11 more
Whit Mayo
Leerink Partners
3 questions for ARDT
Also covers: ACHC, AHCO, ALHC +12 more
BM
Benjamin Mayo
Leerink Partners
2 questions for ARDT
Also covers: ACHC, AGL, AMED +10 more
MM
Michael Murray
RBC Capital Markets
2 questions for ARDT
Also covers: ADUS, AHCO, AMED +9 more
SF
Scott Fidel
Stephens Inc.
2 questions for ARDT
Also covers: ACHC, ADUS, ALHC +17 more
Jason Cassorla
Guggenheim Partners
1 question for ARDT
Also covers: ACHC, CI, CYH +8 more
KF
Kevin Fischbeck
Bank of America
1 question for ARDT
Also covers: AMN, CCRN, CI +9 more
Sarah James
Cantor Fitzgerald
1 question for ARDT
Also covers: ACHC, AMED, CI +16 more
ZS
Zach Silverberg
Wells Fargo
1 question for ARDT
Also covers: RRR
Recent press releases and 8-K filings for ARDT.
Ardent Health Announces Q4 and Full-Year 2025 Results and 2026 Guidance
ARDT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Ardent Health concluded FY 2025 with $6,324 million in total revenue, marking a 6.0% year-over-year increase, and Adjusted EBITDA of $545 million, up 9.3% from the previous year, with 20 basis points of margin expansion.
- The company significantly improved its financial position in FY 2025, with operating cash flow increasing by 49% to $471 million and lease-adjusted net leverage decreasing by 0.4x to 2.5x.
- For Full-Year 2026, Ardent Health projects total revenue between $6,400 million and $6,700 million, Adjusted EBITDA between $485 million and $535 million, and diluted earnings per share ranging from $0.90 to $1.27.
1 day ago
Ardent Health Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance
ARDT
Earnings
Guidance Update
New Projects/Investments
- Ardent Health reported Q4 2025 revenue of $1.61 billion and Adjusted EBITDA of $134 million, exceeding its implied guidance midpoint. For the full year 2025, revenue grew 6% to $6.3 billion and Adjusted EBITDA increased 9% to $545 million, with operating cash flow reaching $471 million, up 49% from 2024.
- The company issued 2026 revenue guidance of $6.4 billion-$6.7 billion and Adjusted EBITDA guidance of $485 million-$535 million. This outlook incorporates an estimated $55 million in savings from its IMPACT program, which helps offset an approximate $35 million headwind from exchange disruption.
- Ardent Health's IMPACT program led to a 0.4% decline in salaries, wages, and benefits year-over-year in Q4 2025 and a 26% reduction in contract labor expenses. While payer denials and professional fees stabilized in Q4 2025, the 2026 outlook does not assume significant improvements in these areas.
1 day ago
Ardent Health Reports Strong 2025 Financial Performance and Issues 2026 Guidance
ARDT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Ardent Health reported full-year 2025 revenue of $6.3 billion, a 6% increase, and Adjusted EBITDA of $545 million, up 9%, with margins expanding 20 basis points to 8.6%.
- The company generated $471 million in operating cash flow in 2025, a 49% increase year-over-year, and strengthened its balance sheet, ending the year with $710 million in cash and reducing lease-adjusted net leverage to 2.5x.
- For 2026, Ardent Health provided Adjusted EBITDA guidance of $485 million-$535 million and revenue guidance of $6.4 billion-$6.7 billion.
- The IMPACT program is now expected to contribute approximately $55 million to Adjusted EBITDA in 2026, an increase from the prior $40 million estimate, with the company anticipating a return to EBITDA growth in 2027.
- In Q4 2025, the company's salaries, wages, and benefits declined 0.4% year-over-year, and contract labor expenses were reduced by 26% to $17 million, demonstrating effective expense optimization.
1 day ago
Ardent Health Reports Record 2025 Financials and Raises 2026 IMPACT Program Savings Target
ARDT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Ardent Health reported record full-year 2025 financial performance, with revenue growing by 6% to $6.3 billion and adjusted EBITDA increasing by 9% to $545 million. Operating cash flow also saw robust growth, up 49% to $471 million, and the balance sheet was strengthened with cash exceeding $700 million and lease-adjusted net leverage reduced to 2.5x.
- The company's IMPACT program is driving significant expense optimization, with Q4 2025 Salaries, Wages, and Benefits (SWB) declining 0.4% year-over-year and contract labor expenses down 26%. The expected contribution from the IMPACT program for 2026 has been raised to approximately $55 million, an increase from the prior $40 million estimate.
- For 2026, Ardent Health provided adjusted EBITDA guidance of $485 million-$535 million and revenue guidance of $6.4 billion-$6.7 billion. This outlook incorporates approximately 4% core earnings growth and the enhanced IMPACT program savings, which are expected to largely offset headwinds from professional fees, payer denials, and an estimated $35 million exchange disruption.
- Ardent Health is strategically deploying AI and other technologies, such as an enterprise-wide AI-assisted virtual care expansion and AI-enhanced Scribe technology, to enhance efficiency and care delivery. These initiatives are aimed at improving workflows, easing staffing pressures, and reducing clinical documentation time by 35% for physicians.
1 day ago
Ardent Health Reports Fourth Quarter 2025 Results
ARDT
Earnings
Guidance Update
Share Buyback
- Ardent Health reported Q4 2025 total revenue of $1.61 billion and net income attributable to Ardent Health of $45 million, with Adjusted EBITDA of $134 million. For the full year 2025, total revenue increased 6.0% to $6.32 billion, and Adjusted EBITDA grew 9.3% to $545 million.
- The company generated robust operating cash flow of $471 million in 2025, up nearly 50% year-over-year, and strengthened its balance sheet with cash exceeding $700 million and a lease-adjusted net leverage ratio of 2.5x at year-end.
- Ardent Health issued full-year 2026 guidance, projecting total revenue between $6,400 million and $6,700 million and Adjusted EBITDA between $485 million and $535 million.
- During Q4 2025, the company repurchased 0.35 million shares of its common stock for $3 million, with $47 million remaining under its repurchase authorization.
2 days ago
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Financial Restatement
Guidance Update
- Faruqi & Faruqi, LLP is investigating Ardent Health (ARDT) for alleged federal securities law violations, with a lead plaintiff deadline of April 21, 2026.
- The class action stems from allegations that Ardent Health made false or misleading statements regarding the collectability of its accounts receivable.
- On November 12, 2025, Ardent Health announced a $43 million decrease in third-quarter 2025 revenue due to a new revenue accounting system, a cut to 2025 EBITDA guidance by $57.5 million at the midpoint (to $530 million – $555 million), and a $54 million increase in professional liability reserves.
- Following these disclosures, Ardent Health's stock price fell nearly 34% to $9.30 per share on November 13, 2025.
8 days ago
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Accounting Changes
Profit Warning
- Faruqi & Faruqi, LLP is investigating Ardent Health (NYSE: ARDT) for potential federal securities law violations, with a March 9, 2026 deadline for investors to seek lead plaintiff status in a class action lawsuit covering losses between July 18, 2024, and November 12, 2025.
- The complaint alleges that the company made false or misleading statements and/or failed to disclose information regarding its accounts receivable and the sufficiency of its professional malpractice liability insurance.
- On November 12, 2025, Ardent announced a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves for the third quarter of 2025.
- Following this news, Ardent's stock price fell 33.81% ($4.75 per share) to close at $9.30 per share on November 13, 2025.
Feb 20, 2026, 3:13 PM
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Accounting Changes
Financial Restatement
- A securities class action lawsuit has been filed against Ardent Health, Inc. (NYSE: ARDT) and certain executives following the company's disastrous Q3 2025 financial results.
- The lawsuit alleges Ardent misled investors about its revenue recognition systems and the adequacy of its professional liability reserves, with a class period from July 18, 2024, to November 12, 2025.
- On November 12, 2025, Ardent revealed a transition to a new accounting method in Q3 2025 for estimating accounts receivable collectability, which resulted in a $42.6 million reduction in revenue and a $47.2 million increase in professional liability reserves.
- Following this disclosure, Ardent's share price tumbled $4.75 (-33%).
Jan 27, 2026, 6:08 PM
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Accounting Changes
Financial Restatement
- A securities class action lawsuit has been filed against Ardent Health (ARDT) and certain executives following the company's "disastrous Q3 2025 financial results".
- The complaint alleges Ardent misled investors about its revenue recognition systems and the adequacy of its professional liability reserves.
- In Q3 2025, Ardent transitioned to a new accounting method, which led to a $42.6 million reduction in revenue and a $47.2 million increase in professional liability reserves.
- This news caused Ardent's share price to drop $4.75 (-33%).
- The class period for investors who purchased securities and suffered substantial losses is between July 18, 2024, and November 12, 2025.
Jan 23, 2026, 3:27 PM
Ardent Health Faces Securities Class Action Over Alleged Accounting Deception
ARDT
Legal Proceedings
Accounting Changes
Financial Restatement
- A securities class action lawsuit has been filed against Ardent Health, Inc. (ARDT) and certain executives by Hagens Berman, alleging investors were misled about the company's revenue recognition systems and professional liability reserves.
- The lawsuit covers a class period from July 18, 2024, to November 12, 2025, with a lead plaintiff deadline of March 9, 2026.
- Allegations state that Ardent did not primarily rely on detailed reviews for accounts receivable collectability, instead utilizing a 180-day cliff at which point an account became fully reserved.
- On November 12, 2025, Ardent revealed a Q3 2025 accounting method transition, which led to a $42.6 million revenue reduction and a $47.2 million increase in professional liability reserves.
- Following this news, Ardent's share price tumbled $4.75 (-33%) the next day.
Jan 21, 2026, 11:37 PM
Quarterly earnings call transcripts for Ardent Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more